Dr. Reddy's Laboratories Limited — Updates, 05-06-2025: Press Release

Dr. Reddy’s has announced a collaboration with Alvotech to develop and commercialize a biosimilar to Keytruda®, a $29.5 billion blockbuster in 2024. This partnership aims to accelerate entry into the high-growth immuno-oncology space by sharing development costs and global commercialization rights. It significantly bolsters Dr. Reddy’s biosimilar pipeline and expands their presence in oncology markets worldwide.